Share
Embed
COGNANO: A Tech-BIO for a new AI drug discovery
London Tech Week Pitch
Akihiro Imura, MD, Ph.D CEO/Founder
COGNANO, Inc.
June 20, 2024
Transcript
10 slides
-
A Tech-BIO for a new AI drug discovery Akihiro Imura,
MD, Ph.D CEO/Founder -
VLPPYTRKKGDMLKGK |||||||| TYDDQRESLLPKEWPR Large Language Model (LLM) The Principle 2023
Drug (antibody) Unknown Target https://arxiv.org/abs/2405.18749 -
Antibody type Conv. antibody VHH Digital information Not suitable Big
Data via NGS VHH VHH: variable domain of heavy chain of heavy chain antibody -
MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQPGGSLTLSCEASDRPLTYFAISWFRQAAGKEREVVSCIGSGATSSNYADSVKGRFTISRDDAKNTVYLQMDSLKPEDTAVYYCAAGSLHCSFNVWRGGDAYDYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQPGGSLRLSCAASGFTFSSNTMSWVRQAPGKGLEWISGIKPGGDTKYADPVRGRFTISRDNAKNTLYLQMDSLKPEDTAVYYCAIGYYGTSARGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLAQPGGSLRLSCAASGFTADKLTWFRQTPGREREGVSCIRTDDASTFYADSVKGRFTISTDDTKTVVYLQMNSLRPEDTGVYYCATDFGSTRQRRCSLKDIGAYTYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQAGGSLRVSCAATGLTFTAYKMGWFRQTPGKAREFVAFIARNGITTHYAEAVKGRFTISRDNAKNTLYLQMNSLRPEDTAMYYCSLTTTGGDYYIPTVDDQYDYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQAGGSLRLSCAASGPTFSSYHIAWFRQAPWKEREFVAAINWSGGSTYYADSVKGRFTISRDNTKNTVYLQMNSLKPEDTAVYYCAVYDEGAAKYDYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQPGGSLSLSCVVSGESFDYYAIGWFRQAPGKEREGVSCISSLGGTTNYADSVKGRFTISRDNAKNTVYLRMNSLKPEDTGVYYCAAVVGGKYFPLCSGGMDYWGKGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGAVQPGGSLRLSCAASGFTLEHYAVAWFRQAPGKEREGVSCISRNDRTSWSADSVRGRFTISRDNAKATVFLQMNNLKPEDTAVYYCATGYSITCSRDYKTYDYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQAGGSLRLSCAASGRTFSAYAMGWFRQAPGKEREFVAGISWTGGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAEELGLGYGSSRYNYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQPGGSLRLSCAASGSTLTYYAIGWFRQAPGKEREGVSCISSSGAYTNYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADIQGKRFPTVQAMCAEYRNYGGMDYWGKGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQPGGHLRLSCVGSGFTLDHYGIGWFRQAPGKGREAISCIGSTGTPNYAENVKGRFTISRDTAKNTVYLQMNRLTPEDTAVYYCAADDWGCIGVIHDSGAEYKYWGQGTQVTVSSHHHHHH
MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQVGDSLRLSCTVSGGVFSNYAMGWFRQAPRKAREFVAGITGDGGSREYADSVEGRFSISRDNAKNTVYLQMNDLKPEDTAVYRCAAERKDTLYRRPSLYDKWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQPGGSLRLSCAASGRTISSRAVGWFRQAPGKEREFVAAINWKGLTTDYADSVQGRFTISRDNAKNTVALEINRLTPEDTAVYYCAAGDSGAPYLSRHPHQWGYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQPGGSLRLSCAGTGFTLEYYAIGWFRQDPGKEREGVSCISTRDGIHYSDSVKGRFTISKDDAKNTVYLQMDSLKPEDSARYHCATVLGPCGRVWYRRGSFGYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQAGGSLRLSCAASGRTFSTDDMAWFRQAPGKEREFVAAINWSGGTTFYRDSVKGRFTISRDNPKNTVYLRMNSLKPEDTAVYYCAGRTRLRIARWQAEDTYDYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQTGGSLRLSCAASGRTFSGEAMGWFRQAPGKEREFTAAISESGRLRSYADSVKGRFTISRDNAKNTVYLQMNGLKPEDTAVYYCAATTLGISREEHNYHYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQAGGSLRLSCAASGRTFSDSAMGWFRQAPGKEREWVASINWTGHETNYADSVKGRFTISRDNAKNTMYLQMNSLKPEDTAVYYCAAASKWGRTTSQNLYDYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQPGGSLRLACTASGFSVDVYSIGWFRQAPGKEYEGLSCISGNGRITNYADSVNGRFTVSRENAKNTVYLQMNSLKPEDTAVYYCAVDRLCTHYTGDYYYSRKGEYDYWGQGTQVTVSSHHHHHH MKYLLPTAAAGLLLLAAQPAMAQVQLQESGGGLVQAGGSLRLSCTASGFTFDDYGIGWFRQAPGKEREGVSSITISDGRPSYADSVKGRFRITSDNAKNTVYLQMNSLKPEDTAVYYCAARSVDYIDYPIDGEVPLPSQSEYEYWGQGTQVTVSSHHHHHH Amino acid residues composing an antibody The first Big Data-Base of labeled Antigen/Antibody VHH https://www.nature.com/scitable/topicpage/cell-differentiation-and- tissue-14046412/ COGNANO Map -
Super Rapid Therapeutics Released against ʻunmet medical needs with no
biomarkerʼ Spring 2024 TNBC Summer 2024 Autumn 2024 Winter 2024 ADC pipelines launched with 2 Biotech companies License-out Collaboration Partnering with academia partnering In-house pipeline In-house pipeline Peer-reviewed reports: https://www.nature.com/articles/s42003-022-03630-3 https://academic.oup.com/jb/article/173/2/115/6840705?login=false https://www.nature.com/articles/s43856-022-00213-5 Patents pending: ・JP 2020-163847 ・PCT/JP 2022/021447 ・JP 2021-170471 ・JP 2022-017180 ・JP 2022-182045 Licensing Spring 2025 Untreated cancers of no biomarker Pancreas & Cholangio Carcinoma - 90K(US) Glioblastoma - 9K(US) Thyroid Anaplastic Carcinoma - 1K(US) Small Cell Lung Cancer - 33K(US) TNBC: Triple Negative Breast Cancer - 300K(Global) world a place where all people live in well-being r of molecular information and technology. get) breast cancer cription cription cription. cription cription cription. cription Description Description Description Description ntreated cancers of biomarker reas & angio noma - US) Glioblastoma - 9K(US) oid Anaplastic Small Cell Lung TNBC: Triple Negative Breast Cancer - 300K(Global) ll people live in well-being ation and technology. treated cancers of biomarker as & ngio oma - ) Glioblastoma - 9K(US) d Anaplastic oma - 1K(US) Small Cell Lung Cancer - 33K(US) TNBC: Triple Negative Breast Cancer - 300K(Global) ption Description Description Description ption Description. Description Description ption Description Description Description. ption Description Description Description ption Description. Description Description ption Description Description Description. Untreated cancers of no biomarker Pancreas & Cholangio Carcinoma - 90K(US) Glioblastoma - 9K(US) Thyroid Anaplastic Carcinoma - 1K(US) Small Cell Lung Cancer - 33K(US) TNBC: Triple Negative Breast Cancer - 300K(Global) Description Description Description Description Description Description. Description Description Description Description Description Description. Description Description Description Description Description Description. Description Description Description Description Description Description. d cancers of rker Glioblastoma - 9K(US) Small Cell Lung Cancer - 33K(US) BC: Triple gative Breast ncer - K(Global) in well-being chnology. ion Description Description ion. Description Description Panc Thyroid Glioblastoma Lung -
Investments Partnerships DB construction (IT) anti-cancer drug (Bio) ASK COGNANO
makes drug discovery rapid and easy.